- Company
- Sam Chun Dang seeks EMA approval for its Eylea biosimilar
- by Nho, Byung Chul Mar 15, 2024 05:48am
- Sam Chun Dang Pharm announced today that its European partner has simultaneously filed for approval of both vial and prefilled syringe formulations of its Eylea biosimilar (SCD411) in Europe. The application is notable as it is the first application filed in Europe following Korea for the prefilled syringe formulation. The application w
- Company
- Yuhan’s external investments totaled KRW 85 bil last year
- by Chon, Seung-Hyun Mar 14, 2024 05:42am
- Yuhan spent a total of KRW 85 billion in external investments. By acquiring equity investments in companies across various sectors, such as biotech venture and health-functional food, Yuhan scouted for additional acquisitions to expand its business areas. According to the Financial Supervisory Service on the 12th, Yuhan made ten external inve
- Company
- Yuhan Corp and BMS will copromote Sotyktu and Zeposia
- by Nho, Byung Chul Mar 13, 2024 05:32am
- Yuhan Corp (CEO: Wook-Je Cho) announced that the company has signed a copromotion agreement with BMS Korea (Country Manager: Hye-Young Lee) for BMS’s plaque psoriasis drug ‘Sotyktu (deucravacitinib)’ and ulcerative colitis drug ‘Zeposia (ozanimod)’ on the 11th. This strategic partnership for joint sales and marketing in Korea marks
- Company
- Bosulif prescriptions now available at general hospitals
- by Eo, Yun-Ho Mar 13, 2024 05:32am
- Bosulif (bosutinib), a drug used to treat leukemia, is now available for prescription at general hospitals. According to the industry sources, Pfizer Korea’s Bosulif, a drug used to treat Chronic Myelogenous Leukemia (CML), has passed the drug committee (DC) of general hospitals, including Seoul National University Hospital, Seoul St.
- Company
- Quadrivalent meningococcal vaccine MenQuadfi approved
- by Eo, Yun-Ho Mar 12, 2024 05:49am
- The quadrivalent meningococcal vaccine MenQuadfi has landed in Korea. The Ministry of Food and Drug Safety granted marketing authorization for Sanofi's invasive meningococcal disease (serogroups A, C, Y, W) vaccine, MenQuadfi (MenACYW-TT) on the 6th. MenQuadfi is a fully liquid quadrivalent meningococcal vaccine that protects against
- Company
- Ilaris’s reimb again at a standstill… bumpy road ahead
- by Eo, Yun-Ho Mar 12, 2024 05:48am
- The road to reimbursement for ‘Ilaris,’ a treatment used by around ten patients in Korea, continues to be bumpy ahead. According to Dailypharm’s coverage, the government’s ‘reimbursement adequacy’ decision made for Novartis Korea’s Ilaris (canakinumab) has been put on hold after the company failed to meet the government's request f
- Company
- SK Bioscience breaks ground on vaccine plant expansion
- by Chon, Seung-Hyun Mar 11, 2024 05:55am
- SK Bioscience announced on the 7th that the company broke ground on a vaccine plant, ‘Andong L HOUSE,’ located in Andong, Gyeongsangbuk-do, South Korea. The plant will be expanded to install new equipment. This expansion aims to increase vaccine production capacity for global supply by raising the existing vaccine plant within L House
- Company
- Jemperli can be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Mar 11, 2024 05:55am
- Jemperli, the first immuno-oncology option introduced to the field of endometrial cancer, can now be prescribed in general hospitals in Korea. According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has passed the drug committee (DC) reviews of tertiary hospitals in Korea. Including the Seoul National University
- Company
- Hemlibra shows big sales rise, Advate loses ground
- by Kim, Jin-Gu Mar 11, 2024 05:55am
- The market for Type A hemophilia has shifted significantly, with JW Pharmaceutical's 'Hemlibra' expanding sales considerably after receiving reimbursement expansion. However, Takeda Pharmaceutical’s 'Advate,' which has been recording the highest sales in the market for an extended period, lost ground. Advate sales decreased by over 20%
- Company
- AZ’s EGPA drug Fasenra receives orphan drug designation
- by Eo, Yun-Ho Mar 11, 2024 05:55am
- AstraZeneca's antibody drug Fasenra has been designated as an orphan drug in Korea for its eosinophilic granulomatosis indication. The Ministry of Food and Drug Safety announced so through an official orphan drug designation notice on the 7th. More specifically, the drug received an orphan drug designation as a treatment for eosinophilic
